(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 1.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Moderna's revenue in 2025 is $3,177,000,000.On average, 10 Wall Street analysts forecast MRNA's revenue for 2025 to be $804,304,642,603, with the lowest MRNA revenue forecast at $744,864,745,320, and the highest MRNA revenue forecast at $952,777,147,752. On average, 10 Wall Street analysts forecast MRNA's revenue for 2026 to be $1,009,195,044,454, with the lowest MRNA revenue forecast at $650,151,286,860, and the highest MRNA revenue forecast at $2,074,212,403,206.
In 2027, MRNA is forecast to generate $1,306,416,575,153 in revenue, with the lowest revenue forecast at $861,703,316,560 and the highest revenue forecast at $3,066,669,261,690.